Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs ProShares Ultra Semiconductors — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.01 (market cap $29.60B), while ProShares Ultra Semiconductors trades at $94.53. The key difference: ProShares Ultra Semiconductors is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | USD | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $113.53 |
52-Week Low | $205.48 | $40.97 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
USD stock trades at $94.98, up 6.62% over 24 hours, with a bullish technical signal from moving averages and a neutral stance from oscillators. The stock shows strong momentum but trades near key resistance at $93. Recent news highlights corporate developments including a dividend announcement scheduled for June 2026, though fundamental data such as P/E and revenue metrics are currently unavailable.
The outlook for USD is cautiously optimistic given technical strength, but limited fundamental data and high RSI levels suggest potential near-term volatility. Investors should weigh the bullish trend against the absence of key financial metrics and elevated technical indicators before making decisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
